anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A polypeptide-containing fat-mobilising substance, FMS-1A, and a polypeptide-containing anorexigenic substance, FMS-1B, are prepared from the urine of fasting or cold-acclimatised animals by addition, at an acidic pH, of an alkanol to give a precipitate, FMS-1, comprising the mixed crude substances, and extracting the precipitate firstly with water to give a solution of FMS-1A and then with dilute aqueous alkali to give a solution of FMS-1B.  The word "anorexigenic" is said to mean capable of causing loss of appetite.  The animals, preferably rats, or horses, goats, sheep, dogs, cows, or rabbits, may be fasted by first feeding on a high fat diet for several days, followed by removal of all food, with urine collection over the next 24 hours; the cold acclimatisation is effected by transfer of the animal kept at room temperature, to an environment at 5 DEG C. for 24 hours to 3 days, with concomitant urine collection.  FMS-1 is precipitated with, e.g. methanol, ethanol or propanol, from the urine acidified to pH 5.3 with benzoic, acetic, hydrochloric or sulphuric acid.  The alkali may be aqueous alkali-metal or alkaline earth metal hydroxide or carbonate.  The two substances FMS-1A and 1B may be purified and obtained in solid form by re-precipitation from the solutions with acidified alcohol, with subsequent dissolution of the precipitate in water or dilute alkali (whichever is appropriate), and lyophilisation.  Also described is the preparation of a similar polypeptide, "Hypox FMS", by the same process but from urine from fasted hypophysectomised rats.  This substance has anorexigenic activity, but no effect upon fat metabolism.  FMS-1A and 1B are also said to cause hypoglycemia.  The invention includes injectable compositions of FMS-1A and 1B with an inert carrier.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmaceutical industry. A supercritical liquid extract of Nerium oleander or Thevetia nerifolia leaves where the extract is prepared by supercritical carbon dioxide liquid extraction; in addition, a supercritical medium contains a modifying agent. The supercritical liquid extract containing oleandrine and another pharmacologically active agent extracted by the supercritical liquid. A pharmaceutical drug containing the supercritical liquid extract for treating a malignant neoplastic disease, cancer, tumour, virus infection or a nonneoplastic inflammatory disease of a skin. A method of treating a disease or disorder answering to a therapeutic cardiac glycoside treatment. A method of inhibition or reduction of degree of Akt phosphorilation in a cancer cell. A method of increasing pERK expression in a cancer cell. A method of inhibition of cancer cell proliferation. A method of supercritical liquid extraction. ^ EFFECT: higher anticancer, antiviral activity. ^ 23 cl, 3 dwg, 18 tbl, 13 ex
Breast cancer patients who underwent surgery with or without chemotherapy, endocrine therapy and/or radiation therapy. The patients are categorized according to the genetic polymorphisms or the activity score of the cytochrome P450 metabolism.
This is a single-center, single-dose, open-label, Phase-1 Positron Emission Tomography (PET) study in 4 healthy volunteers, 2 men and 2 women. After screening, healthy eligible volunteers will be hospitalized in the study unit from study Day 2 to Day 4. On Day 1 (the day before hospitalization), volunteers will enter the study unit from 5:00 p.m. to 8:00 p.m. for baseline prolactin blood sampling and sedation assessment. Each volunteer will have a control magnetic resonance imaging (at screening) and 3 PET measurements using the radioligand \[11\]C raclopride to measure central D2 receptor occupancy in the putamen. Blood samples to measure plasma concentrations of paliperidone will be collect immediately before and at scheduled time points after dose administration on Day 2, and immediately before, halfway through, and immediately after the PET-2 and PET-3 measurements. Serum prolactin levels will be measured immediately before and at several scheduled time points after dose administration, and immediately before and after each PET measurement. At scheduled time points, supine and standing blood pressures, pulse, sensorium changes, temperature, and degree of sedation will be recorded, volunteers will be questioned about adverse events, and they will be evaluated for extrapyramidal symptoms (EPS). Adverse events will be recorded and followed throughout the study. The rationale for the study design is based on previous PET studies with risperidone, which indicated that PET measurement of D2 receptor occupancy after a single dose of medication is useful in predicting an effective clinical dose range. Single oral dose (6 mg) of OROS paliperidone
Hundreds of millions of patients worldwide require pain-relieving therapy to maintain an acceptable quality of life. Pain relievers, including non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, however, exert unwanted potent adverse systemic off-target effects and their use is associated with a well-documented excess of cerebrovascular and cardiovascular events. This of particular concern for the one fourth of the world's population aged over 35 years suffering from chronic pain, particularly with arthritis of whom half also present with established or at high risk of cardiovascular disease. This uncertainty around the cardiovascular safety of pain relieving drugs leaves practitioners and their patients with difficult management decisions and underscores the need to investigate potential differential cardiovascular effects of NSAIDs and opioids and to better delineate the underlying mechanisms involved. Indeed, currently available NSAIDs invariably disrupt the balance between prostacyclin and thromboxane, but may also exert multiple and opposing cardiovascular effects on endothelial factors, including nitric oxide and reactive oxygen species, the sympathetic nervous system and vascular inflammation. Intriguingly, the net effect of pain relieving drugs on vascular function and sympathetic nerve activity and its resulting deterioration of blood pressure control is increasingly recognized as a major possible determinant in explaining the cardiovascular side effects of NSAIDs. As a result of the ongoing concerns around the cardiovascular safety of NSAIDs and coxibs many patients are being withheld effective pain relieve or switched to opioids and/or paracetamol under the assumption of their yet unproven greater cardiovascular safety. The absence of evidence about the cardiovascular safety of these drugs presents a major dilemma for patients and physicians, who have been warned about the toxicity of NSAIDs.
Risk Summary

Hydroxyurea capsules can cause fetal harm based on findings from animal studies and the drug’s mechanism of action [see Clinical Pharmacology (12.1)]. There are no data with hydroxyurea capsules use in pregnant women to inform a drug-associated risk. In animal reproduction studies, administration of hydroxyurea to pregnant rats and rabbits during organogenesis produced embryotoxic and teratogenic effects at doses 0.8 times and 0.3 times, respectively, the maximum recommended human daily dose on a mg/m2 basis (see Data). Advise women of the potential risk to a fetus and to avoid becoming pregnant while being treated with hydroxyurea capsules.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data

Hydroxyurea has been demonstrated to be a potent teratogen in a wide variety of animal models, including mice, hamsters, cats, miniature swine, dogs, and monkeys at doses within 1-fold of the human dose given on a mg/m2 basis. Hydroxyurea is embryotoxic and causes fetal malformations (partially ossified cranial bones, absence of eye sockets, hydrocephaly, bipartite sternebrae, missing lumbar vertebrae) at 180 mg/kg/day (about 0.8 times the maximum recommended human daily dose on a mg/m2 basis) in rats and at 30 mg/kg/day (about 0.3 times the maximum recommended human daily dose on a mg/m2 basis) in rabbits. Embryotoxicity was characterized by decreased fetal viability, reduced live litter sizes, and developmental delays. Hydroxyurea crosses the placenta. Single doses of ≥375 mg/kg (about 1.7 times the maximum recommended human daily dose on a mg/m2 basis) to rats caused growth retardation and impaired learning ability.
A SARS-CoV-2 vaccine comprising an inactivated SARS-CoV-2 particle, a CpG containing oligodeoxynucleotide (CpG-ODN), and an alum adjuvant. The alum adjuvant can be aluminium hydroxide. The vaccine can comprise the oligodeoxynucleotide and alum adjuvant at varying ratios e.g. 1:2. The alum adjuvant can be present at 0.1 to 2 mg/ml. The CpG content of the vaccine can be between 0.25 and 6 mg/ml. The amount of inactivated SARS-CoV-2 virus per dose can be between 0.01 and 25 mAU. The virus particle can be inactivated by beta-propiolactone. The inactivated particle can have amino acid residue modifications in the spike protein, membrane glycoprotein, or nucleocapsid protein. The SARS-CoV-2 vaccine can have a native non-inactivated SARS-CoV-2 particle comprising an RNA sequence which is able to pack a virulent SARS-CoV-2. The CpG-ODN can be CpG 1018. Further aspects of the invention are methods of producing the SARS-CoV-2 vaccine and pharmaceutical compositions comprising the SARS-CoV-2 vaccine for use in prevention or treatment of a SARS-CoV-2 infection e.g. COVID-19.
BACKGROUND AND OBJECTIVES: The anterior ethmoidal artery flap (AEA) is a pedicle endonasal flap frequently used to repair septal perforations (SP). The posterior incision is the most complex to perform. The primary objective was to determine the minimum height of the posterior incision (PI) of an AEA completely cover an anterior septal perforation.
MATERIALS AND METHODS: A cadaveric specimen was sectioned in the sagittal plane and a SP of 1 cm was created anteriorly. The PI of the AEA flap was made progressively at a height of 10, 20, 30, and 40 mm. The complete closure of the SP and the angle of rotation (AR) of the flap were assessed.
RESULTS: According to the length of the PI the following results were obtained: PI = 10 mm: The SP was covered partially, and the AR was 45º. PI = 20 mm: The SP was fully covered, and the AR was 63º. PI = 30 mm and 40 mm: The SP was fully covered with redundant tissue. This study shows that an anterior ethmoidal artery flap that includes the nasal floor and the inferior meatus mucosa combined with a posterior incision of 20 mm could result in adequate coverage of all margins of an anterior SP up to area 1a of the septum.
The patients with Parkinson's Disease will be randomly assigned into two groups: Motor Learning based Clinical Pilates (MLCP) Group and Conventional Physiotherapy (CP) Group. Both groups will be treated for 12 weeks. The evaluation of the patients will be done before the beginning of exercise program, midterm evaluation in the 6th week and will be repeated at the end. Also there will be followed up evaluation with the same assessments at the 3rd month. Physical function/motor function of patients will be evaluated with The Unified Parkinson's Disease Rating Scale (UPDRS) III subscale, dynamic balance with Functional Reach Test (FRT), postural control and dynamic balance will also be evaluated with Berg Balance Scale and functional mobility by Timed Up and Go Test. Gait, balance and functional domains of the patients will be evaluated with Gait and Balance Scale (GABS), Nelson foot reaction test will be used for the reaction time.
Background: Sepsis commonly leads to skeletal muscle atrophy, characterized by substantial muscle weakness and degeneration, ultimately contributing to an adverse prognosis. Studies have shown that programmed cell death is an important factor in the progression of muscle loss in sepsis. However, the precise role and mechanism of pyroptosis in skeletal muscle atrophy are not yet fully comprehended. Therefore, we aimed to examine the role and mechanism of action of the pyroptosis effector protein GSDMD in recognized cellular and mouse models of sepsis. Methods: The levels of GSDMD and N-GSDMD in skeletal muscle were evaluated 2, 4, and 8 days after cecal ligation and puncture. Sepsis was produced in mice that lacked the Gsdmd gene (Gsdmd knockout) and in mice with the normal Gsdmd gene (wild-type) using a procedure called cecal ligation and puncture. The degree of muscular atrophy in the gastrocnemius and tibialis anterior muscles was assessed 72 h after surgery in the septic mouse model. In addition, the architecture of skeletal muscles, protein expression, and markers associated with pathways leading to muscle atrophy were examined in mice from various groups 72 h after surgery. The in vitro investigations entailed the use of siRNA to suppress Gsdmd expression in C2C12 cells, followed by stimulation of these cells with lipopolysaccharide to evaluate the impact of Gsdmd downregulation on muscle atrophy and the related signaling cascades. Results: This study has demonstrated that the GSDMD protein, known as the "executive" protein of pyroptosis, plays a crucial role in the advancement of skeletal muscle atrophy in septic mice. The expression of N-GSDMD in the skeletal muscle of septic mice was markedly higher compared with the control group. The Gsdmd knockout mice exhibited notable enhancements in survival, muscle strength, and body weight compared with the septic mice. Deletion of the Gsdmd gene reduced muscular wasting in the gastrocnemius and tibialis anterior muscles caused by sepsis. Studies conducted in living organisms ( in vivo ) and in laboratory conditions ( in vitro ) have shown that the absence of the Gsdmd gene decreases indicators of muscle loss associated with sepsis by blocking the IL18/AMPK signaling pathway. Conclusion: The results of this study demonstrate that the lack of Gsdmd has a beneficial effect on septic skeletal muscle atrophy by reducing the activation of IL18/AMPK and inhibiting the ubiquitin-proteasome system and autophagy pathways. Therefore, our research provides vital insights into the role of pyroptosis in sepsis-related skeletal muscle wasting, which could potentially lead to the development of therapeutic and interventional approaches for preventing septic skeletal muscle atrophy.
The invention relates to the field of veterinary medicines, and particularly provides an actinobacillus pleuropneumoniae antigen protein composition and application thereof. The antigenic protein composition comprises an ApxIA truncated protein, an ApxIIA truncated protein and an ApxIIIA truncated protein; the amino acid sequence of the ApxIA truncated protein is shown as SEQ ID NO. 2; the amino acid sequence of the ApxIIA truncated protein is shown as SEQ ID NO. 4; the amino acid sequence of the ApxIIIA truncated protein is shown as SEQ ID NO. 6. The composition has good immunogenicity and broad spectrum, and is convenient for production and preparation.
<P>PROBLEM TO BE SOLVED: To develop a modulator for the differentiation from adipocyte's precursor cell to adipocyte and/or the accumulation of adipose in adipocyte.  <P>SOLUTION: The modulator is such that at least one of uridylic acid, uridine and uracil serves as an active ingredient. In the modulator, the modulation includes both of inhibition and promotion. In the case of the former, the accumulation of adipose is inhibited, presenting antiobese effect and also presenting prophylactic and/or curative effects of metabolic syndrome, hypertension, arteriosclerosis, etc.; while, in the case of the latter, the accumulation of adipose is promoted, enabling the production of, for example, marbled beef, i.e. beef with fine streaks of fat.  <P>COPYRIGHT: (C)2008,JPO&INPIT
PCT No. PCT/JP96/01020 Sec. 371 Date Dec. 18, 1997 Sec. 102(e) Date Dec. 18, 1997 PCT Filed Apr. 12, 1996 PCT Pub. No. WO96/32434 PCT Pub. Date Oct. 17, 1996This invention provides a heterotelechelic oligomer or polymer which is represented by the following formula: wherein A denotes a sugar residue, L denotes a linkage group represented by the following formula wherein R1 and R2 independently denote lower alkyl, aralkyl or aryl, X denotes a single bond or -CH2CH-, Z denotes a group forming an unsaturated ester or ether, or a functional group such as halogen which binds to -CH2CH2-, n denotes an integer of 5-10,000, and m denotes an integer of 0 or 2-10,000. This invention also provides a process to produce the above oligomer or polymer, and further a high molecular-micelle with use of a polyethylene oxide-polyester block polymer which has a sugar residue at its terminal. Said oligomer or polymer is expected to exhibit excellent bioavailability, and is also expected to be utilized in the field such as carriers for drug delivery or diagnostic reagents.
Participants first receive a 50-minute standard brief motivational intervention designed to reduce alcohol use. A week later, they will receive the SFAS (Substance-free Activity Session., a 50-minute counseling session designed to increase the salience of the student's academic and career goals, draw attention to the potentially negative relationship between substance use and goal accomplishment, and increase engagement in substance-free alternative activities. The SFAS will be described to participants as the "College Adjustment Session" and the session will be conducted using an MI plus personalized feedback approach.
A dural arteriovenous fistula (dAVF) involving the superior sagittal sinus (SSS) is relatively rare, and its clinical course is usually aggressive. Its concomitance with a tumor has rarely been reported. Here, we present a case of SSS dAVF due to meningioma invasion, which was treated with sinus reconstruction and endovascular embolization. A 75-year-old man who had undergone tumor resection for parasagittal meningioma 4 years prior presented with intra-ventricular hemorrhage. Computed tomography angiography and magnetic resonance imaging revealed recurrent tumor invasion into the SSS causing occlusion. Cerebral angiography revealed multiple shunts along the occluded segment of the SSS, diffuse deep venous congestion, and cortical reflux. Borden type 3 SSS dAVF was diagnosed. We first performed direct tumor resection, followed by stenting for the occluded SSS and partial embolization of the shunts. After a 6-month interval, transvenous occlusion of the SSS was performed along the stent, resulting in complete obliteration of the dAVF. Sinus reconstruction therapy was effective in the immediate improvement of venous hypertension, obtaining the access route to the fistulas, and eradicating the shunts.
FIELD: medicine. SUBSTANCE: method involves a conventional medicinal therapy in combination with additional administration of 200 ml ozonized physiological solution. The latter is administrated by intravenous route, by drops, each other day, for 4-6 procedures. Solution is treated preliminary for 20 min by passage ozone-oxygen mixture containing 600-1200 mcg/l ozone at the rate 1 l/min. Method can be used for complex therapy of patients with vegetal disorders. EFFECT: enhanced effectiveness of treatment. 1 tbl, 3 ex
In recent years, type 2 diabetes mellitus (T2DM) has grown into an emerging pandemic that is a key determinant of morbidity and mortality in both developed and developing countries worldwide. The successful treatment and prevention of T2DM is one of the biggest future health care challenges and most important to manage the enormous socio-economic burden that is associated with T2DM and its various comorbidities. Physical inactivity is known to be one of the most important risk factors for the development of obesity and T2DM. In contrast, increases in physical activity (PA) and fitness can lower the T2DM incidence, improve the patient's glucose metabolism and reduce morbidity and (premature) mortality, independent of body mass index (BMI) or other risk factors. Despite the obvious benefits of regular PA in the treatment and prevention of T2DM, most activity-promoting programs targeting T2DM patients are seldom successful in the long term due to diminishing patient motivation. A novel approach to motivate those individuals that are the least likely to engage in regular PA to be more physically active and adhere to regular PA are active video games or "exergames" that combine PA and video gaming. However, existing exergames do not offer fitness-level adjusted, individualized workouts and are normally stationary and bound to a TV, thus not enabling PA anywhere and at any time. To address these shortcomings, the investigators used sports scientific expertise to develop a smartphone-based, mobile gardening simulation game application, specifically designed for middle-aged T2DM patients, to induce a healthier, more active lifestyle as part of a successful T2DM treatment and management.
Patients receive tivantinib PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
The invention discloses a method for preparing an oil core nano capsule carrier with biocompatibility, stable dispersion and controllable size and wall thickness by a one-step method. The method selects lac as the wall material of the capsule. Firstly, dissolving the lac, the oil phase and the active ingredients in ethanol, then quickly injecting the mixed solution into water through a micro-channel, and quickly dispersing the mixed solution into the water along with the ethanol to be separated out together. The small molecule oil phase and the active ingredients are firstly gathered to form a nano oil core, and then the lac is deposited at the oil-water interface to form a nano capsule wrapping the oil core. The obtained nanocapsule has controllable size and wall thickness, and good dispersibility and stability in water. The nano capsule loaded with the active ingredients prepared by the invention can improve the dispersibility of the active ingredients in water and the stability of the active ingredients during storage, can be used as a novel functional beverage beneficial to human health, and has wide application prospects in the fields of biological medicines, foods, cosmetics and the like.
The invention provides a ginger-red date-fennel-clove-agilawood-containing traditional Chinese medicine composition and a preparation method thereof. The ginger-red date-fennel-clove-agilawood-containing traditional Chinese medicine composition comprises fennel, ginger, red date, clove, agilawood, licorice root and honey according to a ratio. The ginger-red date-fennel-clove-agilawood-containing traditional Chinese medicine composition comprises 120-140g of fennel, 500-600g of ginger, 250-300g of red date, 15-20g of clove bud, 15-20g of agilawood, 90-100g of licorice root and 30-50g of honey. The preparation method comprises adding fennel, ginger, red date, clove, agilawood and licorice root with water of which the amount is 10 times the total amount of the raw materials, putting the mixture into a pot, carrying out boiling by a big fire without an iron-made container, carrying out slow decoction by a warm fire, stopping heating when the 50% of the water in the pot is evaporated, removing impurities by pure cotton gauze, putting the soup into a ceramic container, putting the ceramic container in a place at a temperature below 60 DEG C, adding honey into the soup, carrying out stirring to obtain a uniform mixture, taking 20-30g of the mixture in each morning and taking the mixture with warm water. The traditional Chinese medicine soup has effects of enriching blood, tonifying qi, treating female dual depletion of qi and blood, promoting blood circulation, warming the body and improving sleeping. The ginger-red date-fennel-clove-agilawood-containing traditional Chinese medicine composition is a traditional Chinese medicine formula for treating deficiency-cold in spleen and stomach.
Part 1: Cetuximab, IV over 2 hours, 400 mg/m2 X 1. Part 2: Cetuximab, IV, QW, 400 mg/m2 X 1, over 2 hours, followed by 250mg/m2 X4, over 1 hour for each time.